Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
JAK inhibitors
second malignancy
secondary myelofibrosis
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
27
12
2018
accepted:
27
02
2019
pubmed:
8
6
2019
medline:
4
8
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient-years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.
Identifiants
pubmed: 31173472
doi: 10.1002/cam4.2107
pmc: PMC6675726
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4089-4092Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Leuk Lymphoma. 2016 May;57(5):1197-200
pubmed: 26155828
Leuk Res. 2018 Jun;69:100-102
pubmed: 29734070
Ann Hematol. 2018 Sep;97(9):1591-1600
pubmed: 29804268
Cancer Med. 2019 Aug;8(9):4089-4092
pubmed: 31173472
Leuk Lymphoma. 2016;57(1):237-9
pubmed: 25904378
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Blood. 2018 Aug 16;132(7):694-706
pubmed: 29907599